Phase 2 clinical studies have described that a vaccine based on the tumor antigen MAGE-3, when combined with MPL, QS-21, CpG, and liposomes, displayed better protective efficacy compared to the same antigen combined with MPL, QS-21, and oil-in-water emulsions [61]. This evidence concerns the gene MAGEA3 and neoplasm.